Developing a successful market access strategy requires navigating complex global payer and health technology assessment (HTA) requirements, often across product classes and therapeutic areas. Our Value & Access Consulting experts work to provide actionable strategies to drive and demonstrate payer value throughout the development lifecycle to maximize a product’s success in today’s competitive market. Our experienced team leverages deep relationships with HTA bodies and payers in established and emerging markets to understand what shapes decision making and applies these insights to overcome payer challenges and ensure optimal pricing and access.
New challenges
Health Technology Developers (HTDs) face new challenges on both sides of the Atlantic. In the U.S., the focus is on the impact of the Inflation Reduction Act, while in Europe, the Health Technology Assessment Regulation (HTAR) and the revision of the general pharmaceutical legislation will significantly change the pricing and reimbursement landscape.
Now more than ever, it is critical to engage a global partner with an in-depth understanding of the changing U.S. market access environment
We help you start planning in the early pipeline stages to navigate complex regulatory nuances and give you a competitive advantage.
Understand the implications of the EU HTA Regulation so you can move forward, fearlessly
We bring together pre-clinical, clinical development, and regulatory strategy experience and Thermo Fisher Scientific’s wealth of development expertise to help you move forward with less risk and more efficiency.
